Overview
- Eli Lilly said Kisunla is now available in Germany following recent EU authorization.
- RWTH Aachen expects to start treating eligible patients within one to two weeks.
- Clinical trials reported a slowing of decline over 18 months, amounting to about four to six months’ benefit.
- Donanemab is given by infusion every four weeks and must be initiated by physicians experienced in Alzheimer diagnostics with MRI access.
- Experts estimate fewer than 12,000 people in Germany will qualify due to genetic and anticoagulant exclusions, and they warn of a higher risk of brain edema or microbleeds than with lecanemab, with lower efficacy observed in women.